Published online before print February 23, 2004, doi: 10.1161/01.CIR.0000118464.48959.1C
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:1674-1679.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure
From INSERM U644 (IFRMP No. 23) (P.M., S.B., A.C., V.R., J.P.H., F.L., S.R., C.T.), UFR de Médecine et de Pharmacie, Rouen, France, and Institut de Recherches Internationales Servier (G.L., F.M.-G.), Courbevoie, France.
Correspondence to Prof C. Thuillez, INSERM U644, Faculté de Médecine et Pharmacie, 22 Boulevard Gambetta, 76183 Rouen Cedex, France. E-mail Christian.Thuillez{at}chu-rouen.fr
Received March 31, 2003; de novo received July 15, 2003; revision received November 14, 2003; accepted November 17, 2003.
Background— Heart rate reduction (HRR) improves left ventricular (LV) filling, increases myocardial O2 supply, and reduces myocardial O2 consumption, which are all beneficial in congestive heart failure (CHF). However, the long-term effects of HRR on cardiac function and remodeling are unknown.
Methods and Results— We assessed, in rats with CHF, the effects of long-term HRR induced by the selective If current inhibitor ivabradine (as food admix for 90 days starting 7 days after coronary artery ligation). To assess intrinsic modifications of LV tissue induced by long-term HRR, all parameters were reassessed 3 days after interruption of treatment. Ivabradine decreased heart rate over the 90-day treatment period (–18% versus untreated at 10 mg · kg–1 · d–1), without modifying blood pressure, LV end-diastolic pressure, or dP/dtmax/min. Ivabradine significantly reduced LV end-systolic but not end-diastolic diameter, which resulted in preserved cardiac output due to increased stroke volume. In the Langendorff preparation, ivabradine shifted LV systolic but not end-diastolic pressure-volume relations to the left. Ivabradine decreased LV collagen density and increased LV capillary density without modifying LV weight. Three days after interruption of treatment, the effects of ivabradine on LV geometry, shortening, and stroke volume persisted despite normalization of heart rate.
Conclusions— In rats with CHF, long-term HRR induced by the selective If inhibitor ivabradine improves LV function and increases stroke volume, preserving cardiac output despite the HRR. The improvement of cardiac function is related not only to the HRR per se but also to modifications in the extracellular matrix and/or function of myocytes as a consequence of long-term HRR.
Key Words: heart failure • heart rate • drugs • pathology
This article has been cited by other articles:
 |
|
 |
|
  K. Swedberg, M. Komajda, M. Bohm, J. S. Borer, I. Ford, and L. Tavazzi Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) Eur J Heart Fail, November 5, 2009; (2009) hfp154v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif Heart rate and atherosclerosis Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D8 - D12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease) Eur. Heart J. Suppl., August 1, 2009; 11(suppl_D): D19 - D27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Christensen, R.-l. Zhang, W. Zheng, J. J. Campanelli, E. I. Dedkov, R. M. Weiss, and R. J. Tomanek Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H322 - H330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif Heart rate as a treatable cardiovascular risk factor Br. Med. Bull., June 1, 2009; 90(1): 71 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Maurer, J. D. Sackner-Bernstein, L. El-Khoury Rumbarger, M. Yushak, D. L. King, and D. Burkhoff Mechanisms Underlying Improvements in Ejection Fraction With Carvedilol in Heart Failure Circ Heart Fail, May 1, 2009; 2(3): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Milliez, S. Messaoudi, J. Nehme, C. Rodriguez, J.-L. Samuel, and C. Delcayre Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H435 - H441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Logeart, J.-P. Gueffet, F. Rouzet, F. Pousset, C. Chavelas, A. C. Solal, and G. Jondeau Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a pilot study Eur J Heart Fail, January 1, 2009; 11(1): 53 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nagele, W. Rodiger, and M. A. Castel Rate-responsive pacing in patients with heart failure: long-term results of a randomized study Europace, October 1, 2008; 10(10): 1182 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Heusch, A. Skyschally, P. Gres, P. van Caster, D. Schilawa, and R. Schulz Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction Eur. Heart J., September 2, 2008; 29(18): 2265 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, C. Ceconi, and G. Guardigli Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F7 - F10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Zamorano Heart rate management: a therapeutic goal throughout the cardiovascular continuum Eur. Heart J. Suppl., August 1, 2008; 10(suppl_F): F17 - F21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Goldstein and M. C.P. Haigney Heart-rate reduction and {beta}-blockade in early post-infarction cardiac remodelling Cardiovasc Res, July 1, 2008; 79(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
|
|
M. Maczewski and U. Mackiewicz Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart Cardiovasc Res, July 1, 2008; 79(1): 42 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. De Ferrari, A. Mazzuero, L. Agnesina, A. Bertoletti, M. Lettino, C. Campana, P. J. Schwartz, and L. Tavazzi Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure Eur J Heart Fail, June 1, 2008; 10(6): 550 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishio, Y. Sakata, T. Mano, T. Ohtani, Y. Takeda, T. Miwa, M. Hori, T. Masuyama, T. Kondo, and K. Yamamoto Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats Eur J Heart Fail, May 1, 2008; 10(5): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-F. Yeih, L.-Y. Lin, H.-I Yeh, Y.-J. Lai, F.-T. Chiang, C.-D. Tseng, S.-H. Chu, and Y.-Z. Tseng Temporal changes in cardiac force- and flow-generation capacity, loading conditions, and mechanical efficiency in streptozotocin-induced diabetic rats Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H867 - H874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ciobotaru, M. Heimburger, L. Louedec, C. Heymes, R. Ventura-Clapier, P. Bedossa, B. Escoubet, J.-B. Michel, J.-J. Mercadier, and D. Logeart Effect of Long-Term Heart Rate Reduction by If Current Inhibition on Pressure Overload-Induced Heart Failure in Rats J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Heusch and R. Schulz The role of heart rate and the benefits of heart rate reduction in acute myocardial ischaemia Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F8 - F14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Swedberg Pure heart rate reduction: further perspectives in heart failure Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F20 - F24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fox, J. S. Borer, A. J. Camm, N. Danchin, R. Ferrari, J. L. Lopez Sendon, P. G. Steg, J.-C. Tardif, L. Tavazzi, M. Tendera, et al. Resting Heart Rate in Cardiovascular Disease J. Am. Coll. Cardiol., August 28, 2007; 50(9): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I. Dedkov, W. Zheng, L. P. Christensen, R. M. Weiss, F. Mahlberg-Gaudin, and R. J. Tomanek Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H590 - H598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lucats, B. Ghaleh, X. Monnet, P. Colin, A. Bize, and A. Berdeaux Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning Eur. Heart J., April 1, 2007; 28(7): 872 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Camm How does pure heart rate lowering impact on cardiac tolerability? Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D9 - D15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Steg and D. Tchetche Pharmacologic management of stable angina: role of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D16 - D23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif and C. Berry From coronary artery disease to heart failure: potential benefits of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D24 - D29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-L. Leoni, C. Marionneau, S. Demolombe, S. L. Bouter, M. E. Mangoni, D. Escande, and F. Charpentier Chronic heart rate reduction remodels ion channel transcripts in the mouse sinoatrial node but not in the ventricle Physiol Genomics, December 14, 2005; 24(1): 4 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H16 - H21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fox Future perspectives of If inhibition in various cardiac conditions Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H33 - H36. [Abstract] [Full Text] [PDF]
|
|